Biovitrum Ab

Biovitrum Ab (publ)

Other

Proximagen Limited

Helena Lundström

Magnus Cernerud

Alexander Paptchikhine

Margit Pelcman

Alf Nygren

Emma Andersson

Claes Löfström

Tom Fleck

Bruce Fleck, Legal Representative

Björn M Nilsson

Markus Thor

The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R-Rare each independently selected from the group consisting of hydrogen, halogen, C-C-alkyl, C-C-alkoxy, and di-C-C-alkylamino-C-C-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases

(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof

Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine

Stable acid addition salts of certain 2,3-disubstituted pyrazine compounds that are selective for the 5-HT2c receptor and therapeutically active in the central nervous system are described.

Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine

Compounds of the general formula (I):  Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HTreceptor-related disorders or medical conditions.

Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones

The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R&#x2013;Rare each independently selected from the group consisting of hydrogen, halogen, C&#x2013;C-alkyl, C&#x2013;C-alkoxy, and di-C&#x2013;C-alkylamino-C&#x2013;C-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds

Growing community of inventors

Sundbyberg, Sweden

Helena Lundström